Arndt Vogel (@ArndtVogel) header
Arndt Vogel (@ArndtVogel) profile picture

Clinician-Scientist, ESMO Ambassador, focussed on Liver Cancer & Precision Oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪

Hannover
Joined February 2013
Photo by Arndt Vogel (@ArndtVogel)Photo by Arndt Vogel (@ArndtVogel)Photo by Arndt Vogel (@ArndtVogel)Photo by Arndt Vogel (@ArndtVogel)Photo by Arndt Vogel (@ArndtVogel)Photo by Arndt Vogel (@ArndtVogel)Photo by Arndt Vogel (@ArndtVogel)Photo by Arndt Vogel (@ArndtVogel)Photo by Arndt Vogel (@ArndtVogel)
Arndt Vogel retweeted
Thank you Colleagues for a phenomenal #ESMO26 ESMO in Madrid is a wrap, and we are grateful to everyone who shared, discussed, debated and amplified the science this week. You turned five days in Madrid into a truly global conversation. 🌍 OUR Network's MISSION: Keep our colleagues worldwide Up To date in REAL TIME. 📣 101.7M impressions of potential reach 💬 6.1K posts on X from 988 participants in 34 countries ⚡ 43.1 posts per hour across the meeting days 😊 45% positive sentiment, with only 6% negative Real-time metrics powered by ACUVOX. WWW.ACUVOX.IO 🏆 Top influencers @DrChoueiri, @StephenVLiu, @PTarantinoMD, @dr_yakupergun, @HHorinouchi, @zklaassen_md, @stolaney1, @ArndtVogel, @DrYukselUrun, @DraMartinezLago, @tompowles1, @SuyogCancer, @adamfeuerstein, @ScaltritiLab, @GIMedOnc, @ScottGottliebMD, @barriere_dr, @_ShankarSiva, @miriamgonp, @TiansterZhang, @matteolambe, @NiuSanford, @christine_lovly, @amerseburger, @GlopesMd, @montypal, @Icro_Meattini, @PGrivasMDPhD, @brian_rini, @CathyEngMD, @apolo_andrea, @AndreaNecchi, @DrSGraff, @graokane, @to_be_elizabeth, @ElisaAgostinett, @nataliagandur, @UOzkerim, @DrMirallas, @Lucarecco, @mzugman, @p_ciracimd, @DrVilmaPBarcia, @MarioBalsaMD, @scocmem, @GaiaGriguolo, @JankovicK, @Dr_Oncologista 🌎 Where the conversation came from North America led with 1,940 posts, followed closely by Europe with 1,777. Boston, Madrid and New York were the most active cities. 🔬 Top studies by impact 1️⃣ DeLLphi-305 (SCLC): 4.0M reach, 170 posts 2️⃣ VOLGA (bladder): 3.7M reach, 141 posts 3️⃣ KRASCENDO-1 (NSCLC): 3.5M reach 4️⃣ SAFFRON (NSCLC): 3.3M reach 5️⃣ INTerpath-001 (melanoma): 154 posts Pinging our Collaborators
17
4
45
9,312
Pivotal Phase 2 study of derazantinib for previously-treated CCA with FGFR2 aberrations: FIDES-01 @HEP_Journal doi.org/10.1097/HEP.00000000… 👉ORR 22%, DCR 72%, mPFS 8.2 mo, mOS 17.2 mo 👉some efficacy in mut/amp GA 🧐Overall consistency, and Pemi, Futi & Lira approved @myESMO @ASCO @EASLnews @ILCAnews
14
32
1,534
s.c envafolimab + GEMOX vs GEMOX alone as 1L treatment for BTC in Chinese patients: A randomized, ph III trial #ESMO26 #ESMOAmbassadors 👉ORR: 27 vs 20% 👉 mPFS: 5.4 vs 4.5 mo 👉 mOS: 10.9 8.6 mo 🧐Confirms KN-966 & TOPAZ-1 in 🇨🇳pts @myESMO @ASCO
1
8
1
15
940
OPTIMUM: phase 2 study of maintenance olaparib +/-Durva in DDR gene-mutated aBTC #ESMO26 #ESMOAmbassadors 👉ORR 44% response during induction CTx 👉ORR 39% vs 25% 👉 6mo PFS-rate : 62 vs 62% 👉 mOS: 16 vs 29 mo 🧐Neg study, but very promising signal, requires further investigations @myESMO @ASCO
10
19
1,149
Phase I study of C-CAR031, a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in HCC: Updated results #ESMO26 #ESMOAmbassadors 👉ORR: 40.4%, all PR, DCR 94% 👉mOS: 18 mo 🧐Impressive response, and interesting OS, needs confirmation in western populations @myESMO @ASCO
2
14
18
1,294
LEAP-012 study of lenvatinib + pembrolizumab vs plc with TACE for HCC: Long-term OS results #ESMO26 #ESMOAmbassadors 👉ORR: 48 vs 33.7% 👉 mPFS: 14.6 vs 10.2 mo 👉 mOS: 40.4 vs 40.8 mo 🧐 Higher ORR & PFS did not translate into OS, a bit disappointing @myESMO @ASCO
1
29
1
38
2,506
Safety & efficacy of INCB161734, a oral KRAS G12D inh, in combination with GEMNab or FOLFIRINOX in mPDAC #ESMO26 #ESMOAmbassadors 👉ORR: 69 vs 89%, no PD 👉mPFS: 👉GI & hemato toxicity, but no skin tox 🧐very impressive, combination with both CTx feasible, ph 3 ongoing @myESMO @ASCO
4
28
1
79
7,293
HRS-4642 plus CTx ± adebrelimab as perioperative therapy in KRAS G12D-mPDAC: Preliminary results of a phase 2 study #ESMO26 #ESMOAmbassadors 👉ORR: 63 vs 87% 👉Manageable safety 🧐 exciting results, tumor shrinkage in all pts, added benefit of ICI remains to be seen @myESMO @ASCO
11
1
18
1,202
🔥Presidential session at ESMO 2026 🔥 HARMONi-GI1 ph-3: Ivonescimab + CTx vs durvalumab + CTx as 1L for BTC #ESMO26 #ESMOAmbassadors 👉ORR: 53.8 vs. 32.5 % 👉mPFS: 8.4 vs 5.8 mo 👉mOS: 14.9 vs. 12.1 mo 🧐 Very promising Chinese data, would be great to see data in a global population @myESMO @ASCO
3
36
1
57
3,314
🔥Presidential session at ESMO 2026 🔥 CLARITY-Gastric 01: Ph 3 of sonesitatug vedotin in 2L+ CLDN18.2-positive GEC #ESMO26 #ESMOAmbassadors 👉ORR: 23 vs 13% 👉mPFS: 4.2 vs 3.8 mo 👉mOS: 10 vs 5 mo 👉No new safety signals 🧐 exciting results, new option for 2L+ CLDN18.2+ pts @myESMO @ASCO
3
29
56
3,495
DFS and OS after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial @TheLancet doi.org/10.1016/S0140-6736(2… 👉💯% DFS 👉💯% OS 👏does not need any comment @myESMO @ASCO
4
53
1
115
6,647
Final OS results from CheckMate 8HW: Nivo plus ipi vs nivo or CTx in MSI-H/dMMR mCRC #ESMO26 #ESMOAmbassadors 👉ORR 72% 58% 👉mOS: NR --> NI vs N HR 0.66 👉5-yr for Nivo/Ipi: 77% 🧐Convincing, Nivo + Ipi as SOC in 1L MSI CRC @myESMO @ASCO
1
33
42
2,393
Biweekly vs conventional trifluridine/tipiracil plus bevacizumab for refractory mCRC: The pragmatic ph 3 PRABITAS trial #ESMO26 #ESMOAmbassadors 👉ORR: 2 vs 2% 👉 mPFS: 3.9 vs 3.9 mo 👉 mOS: 10.3 vs 11.3 mo 🧐similar efficacy, less toxicity, supports biweekly schedule @myESMO @ASCO
30
3
73
4,978
Long-term follow-up of Temab-A with Bev vs SOC in 3L+ CRC: Updated results of a ph 1 #ESMO26 #ESMOAmbassadors 👉 mPFS: 6.8 vs 4.2 mo 👉 mOS: 14.7 vs 10.2 mo 👉 manageable safety 🧐Promising, ph-3 ongoing @myESMO @ASCO
9
11
1,026
Preliminary clinical results of QTX3034, an oral G12D-preferring KRAS inhibitor with cetuximab ± mFOLFOX6 in KRASG12D-mCRC #ESMO26 #ESMOAmbassadors 👉ORR: 25% vs 50%, DCR: 75 vs 90% 👉 no new safety signals 🧐Supports the combination with CTx @myESMO @ASCO
14
1
16
1,433
TRIDENTE: A phase II study of rechallenge with ENCO, BINI, and CET in BRAF V600E-mutant mCRC #ESMO26 #ESMOAmbassadors 👉mPFS: 2.8 mo 👉mOS: 9.6 mo 👉ORR: 19% 🧐Supports biomarker-driven re-challenging concepts for 🎯therapies in CRC @myESMO @ASCO
16
1
23
1,447
Encorafenib plus cetuximab beyond progression in combination with FOLFIRI in BRAF V600E mCRC progressing on EC: Results from the ECLYPse phase II trial #ESMO26 #ESMOAmbassadors 👉 mPFS: 7.1 👉 mOS: NR 👉ORR 15% 🧐Interesting signal to continue EC, more translational data would be great @myESMO @ASCO
1
24
2
39
4,138
Phase I study of BGB-B2033 (GPC3 x 4-1BB bispecific AB): Dose optimization and escalation update in advanced HCC #ESMO26 #ESMOAmbassadors 👉ORR: 30% 👉manageable safety 🧐very promising agent, looking forward to see combination with ICI @myESMO @ASCO
1
19
2
28
3,576
Liver function trajectory & post-progression outcomes in the pts 3 EMERALD-3 study of STRIDE ± Lenva + TACE in HCC #ESMO26 #ESMOAmbassadors 👉 liver function maintained 👉 similar subsequent therapies 🧐No overal OS benefit, but interesting OS signal for STRIDE in ALBI 1 pts @myESMO @ASCO
12
21
1,303